Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer
- 454 Downloads
This aim of this study was to evaluate the relationship between hexokinase II expression and chemoresistance in epithelial ovarian cancer. One hundred and eleven paraffin-embedded specimens from patients with epithelial ovarian cancer were immunohistochemically stained for hexokinase II. Subsequently, the association between hexokinase II overexpression and clinicopathologic characteristics including chemoresistance was assessed. Survival analyses were also performed for evaluating the prognostic value of hexokinase II overexpression. Tumor recurrence within 6 months after termination of first-line chemotherapy was considered to indicate chemoresistance. Hexokinase II overexpression was associated with chemoresistance (p = 0.029) and was an independent risk factor for chemoresistance [odds ratio (OR) 3.37; 95 % confidence interval (CI) 1.07–10.62; p = 0.038] along with non-optimal debulking surgery (OR 4.93; 95 % CI 1.43–16.98; p = 0.011). Hexokinase II overexpression was significantly associated with decreased progression-free survival (p = 0.002) and showed a similar trend for overall survival (p = 0.101). Cox regression analysis revealed that hexokinase II overexpression was an independent prognostic factor for early recurrence (hazard ratio 2.63; 95 % CI 1.40–4.92; p = 0.002). Our findings suggest that hexokinase II overexpression is associated with short progression-free survival, which could be associated with chemoresistance in epithelial ovarian cancer.
KeywordsHexokinase Immunohistochemistry Drug resistance Recurrence Ovarian cancer
This work was supported by grant from the SNUH Research Fund (No. 0320120350). This research was also supported by Basic Science Research Program (No. 2011-0025394), WCU (World Class University) program (R31-10056), and Priority Research Centers Program (No. 2009-0093820) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.
Conflict of interest
The authors indicate no potential conflict of interest.
- 2.Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27(16):2686–2691. doi:10.1200/JCO.2008.19.2963 PubMedCentralPubMedCrossRefGoogle Scholar
- 6.Fabian C, Koetz L, Favaro E, Indraccolo S, Mueller-Klieser W, Sattler UG (2012) Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS J 279(5):882–891. doi:10.1111/j.1742-4658.2012.08479.x PubMedCrossRefGoogle Scholar
- 8.Pedersen PL (2007) Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(3):211–222. doi:10.1007/s10863-007-9094-x PubMedCrossRefGoogle Scholar
- 15.Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, Saga T, Togashi K (2007) Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Investig 25(3):154–162. doi:10.1080/07357900701208931 CrossRefGoogle Scholar
- 18.Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-d-glucose positron emission tomography. Cancer Sci 99(2):260–266. doi:10.1111/j.1349-7006.2007.00683.x PubMedCrossRefGoogle Scholar
- 21.Milane L, Duan Z, Amiji M (2011) Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int 11:3. doi:10.1186/1475-2867-11-3 PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A, Higuchi I, Yoshikawa H, Aozasa K, Hatazawa J (2008) 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 22(8):699–705. doi:10.1007/s12149-008-0173-9 PubMedCrossRefGoogle Scholar
- 32.Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Shih IM, Bristow RE (2007) Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 17(3):601–606. doi:10.1111/j.1525-1438.2007.00820.x PubMedCrossRefGoogle Scholar
- 35.Lee HP (2007) Annual report of gynecologic cancer registry program in Korea for 2004. Korean J Obstet Gynecol 50(1):28–78Google Scholar